NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

8.33%

16.5¢

Market Cap $54.87M

Healthcare Biotechnology

NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is... NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn and EmtinBn). EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Its StemSmart is a global patented technology engaged in manufacturing cell products. The use of its proprietary StemSmart technology in a special access program for fistulising Crohn’s disease.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NSB	2025 Annual Report & Appendix 4E	PRICE SENSITIVE	28/08/25	1.96MB	Share
NSB	Previous StemSmart Studies Support Renal Transplantation	PRICE SENSITIVE	27/08/25	308.92KB	Share
NSB	Experienced Cell Therapy Executive Appointed CEO	PRICE SENSITIVE	28/07/25	470.44KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/25	1.35MB	Share
NSB	StemSmart Acquisition Complete	PRICE SENSITIVE	27/06/25	529.19KB	Share
NSB	Previous StemSmart Studies Demonstrate Clinical Response	PRICE SENSITIVE	19/06/25	738.35KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/25	1.3MB	Share
NSB	NeuroScientific to Acquire Leading Stem Cell Technology	PRICE SENSITIVE	16/04/25	700.95KB	Share
NSB	Trading Halt	PRICE SENSITIVE	14/04/25	920.7KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/25	3.53MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	1.33MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/24	1.32MB	Share
NSB	2024 Annual Report & Appendix 4E	PRICE SENSITIVE	29/08/24	6.37MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	19/07/24	1.23MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/24	1.31MB	Share
NSB	Appointment of Executive Director & FDA Pre-Ind Meeting	PRICE SENSITIVE	02/04/24	416.34KB	Share
NSB	NSB Receives A$2.2M Research & Development Tax Refund	PRICE SENSITIVE	20/03/24	410.52KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	1.01MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	311.96KB	Share
NSB	Resignation of CEO	PRICE SENSITIVE	01/12/23	178.63KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	357.42KB	Share
NSB	Appointment of CEO	PRICE SENSITIVE	31/08/23	154.04KB	Share
NSB	2023 Annual Report and Appendix 4E	PRICE SENSITIVE	25/08/23	1.6MB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	339.28KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	309.87KB	Share
NSB	Positive treatment effect in MS animal study	PRICE SENSITIVE	14/03/23	1.06MB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.2MB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	02/02/23	116.37KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	283.22KB	Share
NSB	NSB files new patent	PRICE SENSITIVE	05/12/22	434.32KB	Share
NSB	Appointment of Interim CEO	PRICE SENSITIVE	23/11/22	170.98KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	283.14KB	Share
NSB	Investor Update Presentation	PRICE SENSITIVE	20/09/22	1.05MB	Share
NSB	CEO Resignation	PRICE SENSITIVE	09/09/22	124.53KB	Share
NSB	HREC decision to not approve Phase I Clinical Trial	PRICE SENSITIVE	07/09/22	129.59KB	Share
NSB	NeuroScientific releases FY2022 Results	PRICE SENSITIVE	30/08/22	223.9KB	Share
NSB	2022 Annual Report and Appendix 4E	PRICE SENSITIVE	30/08/22	1.85MB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	17/08/22	139.55KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	292.44KB	Share
NSB	HREC Submission for Phase I Clinical Trial	PRICE SENSITIVE	12/07/22	138.38KB	Share
NSB	First Subject Recruited for Early-Phase Clinical Trial	PRICE SENSITIVE	30/06/22	142.11KB	Share
NSB	Positive results in MS animal study	PRICE SENSITIVE	15/06/22	147.01KB	Share
NSB	Ethics Approval Granted for Early-Phase Clinical Trial	PRICE SENSITIVE	07/06/22	140.53KB	Share
NSB	HREC Submission for early-phase Clinical Trial	PRICE SENSITIVE	11/05/22	149.59KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	284.15KB	Share
NSB	Positive safety result supports advance to clinical trials	PRICE SENSITIVE	13/04/22	144.93KB	Share
NSB	New data demonstrates EmtinB activity in autoimmune diseases	PRICE SENSITIVE	11/03/22	258.11KB	Share
NSB	NSB 1HY22 Key Activity Highlights	PRICE SENSITIVE	28/02/22	223.32KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	885.91KB	Share
NSB	Successful completion of key studies in lead up to Phase I	PRICE SENSITIVE	08/02/22	144.51KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	300.57KB	Share
NSB	Positive off-target safety assessment of EmtinB	PRICE SENSITIVE	24/12/21	144.05KB	Share
NSB	Positive results in biomarker characterisation of Emtins	PRICE SENSITIVE	21/12/21	421.77KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	279.9KB	Share
NSB	Completion of Safety Pharmacology Studies	PRICE SENSITIVE	18/10/21	143.03KB	Share
NSB	NSB Receives R&D Advance & Overseas Finding	PRICE SENSITIVE	03/09/21	114.12KB	Share
NSB	Positive Results in Multiple Sclerosis Study	PRICE SENSITIVE	31/08/21	248.06KB	Share
NSB	2021 Annual Report and Appendix 4E	PRICE SENSITIVE	27/08/21	910.83KB	Share
NSB	Results from Pulmonary Studies Clarification	PRICE SENSITIVE	20/08/21	159.86KB	Share
NSB	Trading Halt	PRICE SENSITIVE	19/08/21	587.81KB	Share
NSB	Pause in Trading	PRICE SENSITIVE	19/08/21	118.08KB	Share
NSB	Results from Pulmonary Studies	PRICE SENSITIVE	19/08/21	161.11KB	Share
NSB	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/07/21	349.07KB	Share
NSB	Successful completion of pivotal ocular safety study	PRICE SENSITIVE	01/07/21	169.24KB	Share
NSB	Trading Halt	PRICE SENSITIVE	30/06/21	589.64KB	Share
NSB	Pause in Trading	PRICE SENSITIVE	30/06/21	117.12KB	Share
NSB	NSB partners with Linear Research for Phase I Clinical Study	PRICE SENSITIVE	23/06/21	174.21KB	Share
NSB	R&D Tax Rebate Received	PRICE SENSITIVE	31/05/21	106.28KB	Share
NSB	Update on Pivotal Ocular Safety Studies	PRICE SENSITIVE	05/05/21	618.43KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/21	280.13KB	Share
NSB	Manufacturing Update	PRICE SENSITIVE	28/04/21	81.69KB	Share
NSB	Key Executive Appointments to Support Clinical Studies	PRICE SENSITIVE	31/03/21	109.58KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	458.12KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	298.77KB	Share
NSB	NSB to investigate treatment for post-COVID Fibrosis	PRICE SENSITIVE	20/11/20	219.65KB	Share
NSB	Trading Halt	PRICE SENSITIVE	19/11/20	264.08KB	Share
NSB	Strategic Placement to AlphaSwiss Partners	PRICE SENSITIVE	11/11/20	130.2KB	Share
NSB	Trading Halt	PRICE SENSITIVE	09/11/20	601.76KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/20	321.92KB	Share
NSB	Appendix 4E and Annual Report	PRICE SENSITIVE	28/08/20	911.6KB	Share
NSB	Updated Appendix 4C	PRICE SENSITIVE	12/08/20	315.52KB	Share
NSB	Full Report from Multiple Sclerosis Study	PRICE SENSITIVE	04/08/20	349.04KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/20	302.15KB	Share
NSB	EmtinB Positive Results in MS	PRICE SENSITIVE	14/07/20	203.32KB	Share
NSB	Final Report received for Glaucoma Study	PRICE SENSITIVE	04/05/20	267.07KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/20	710.11KB	Share
NSB	Positive Results in MS Study	PRICE SENSITIVE	18/03/20	454.02KB	Share
NSB	Trading Halt	PRICE SENSITIVE	16/03/20	429.56KB	Share
NSB	Positive Results in Glaucoma Pig Model	PRICE SENSITIVE	11/03/20	167.4KB	Share
NSB	Trading Halt	PRICE SENSITIVE	09/03/20	113.9KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	348.73KB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	177.13KB	Share
NSB	Additional US Patent granted	PRICE SENSITIVE	22/01/20	153.53KB	Share
NSB	CVN Model Indicates Neuroprotective Properties of EmtinB	PRICE SENSITIVE	06/12/19	399.54KB	Share
NSB	NSB - Company Update	PRICE SENSITIVE	02/12/19	172.05KB	Share
NSB	AGM Address	PRICE SENSITIVE	29/11/19	1.51MB	Share
NSB	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/19	176.85KB	Share
NSB	EmtinB Can Become a Revolutionary Treatment for Glaucoma	PRICE SENSITIVE	01/10/19	398.9KB	Share
NSB	Trading Halt	PRICE SENSITIVE	27/09/19	239.28KB	Share
NSB	NSB Receives R&D Advanced Overseas Finding	PRICE SENSITIVE	02/09/19	153.46KB	Share

NSB 2025 Annual Report & Appendix 4E
28/08/25	PRICE SENSITIVE	1.96MB	Share
NSB Previous StemSmart Studies Support Renal Transplantation
27/08/25	PRICE SENSITIVE	308.92KB	Share
NSB Experienced Cell Therapy Executive Appointed CEO
28/07/25	PRICE SENSITIVE	470.44KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
23/07/25	PRICE SENSITIVE	1.35MB	Share
NSB StemSmart Acquisition Complete
27/06/25	PRICE SENSITIVE	529.19KB	Share
NSB Previous StemSmart Studies Demonstrate Clinical Response
19/06/25	PRICE SENSITIVE	738.35KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
24/04/25	PRICE SENSITIVE	1.3MB	Share
NSB NeuroScientific to Acquire Leading Stem Cell Technology
16/04/25	PRICE SENSITIVE	700.95KB	Share
NSB Trading Halt
14/04/25	PRICE SENSITIVE	920.7KB	Share
NSB Half Yearly Report and Accounts
26/02/25	PRICE SENSITIVE	3.53MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	1.33MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/10/24	PRICE SENSITIVE	1.32MB	Share
NSB 2024 Annual Report & Appendix 4E
29/08/24	PRICE SENSITIVE	6.37MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
19/07/24	PRICE SENSITIVE	1.23MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/24	PRICE SENSITIVE	1.31MB	Share
NSB Appointment of Executive Director & FDA Pre-Ind Meeting
02/04/24	PRICE SENSITIVE	416.34KB	Share
NSB NSB Receives A$2.2M Research & Development Tax Refund
20/03/24	PRICE SENSITIVE	410.52KB	Share
NSB Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	1.01MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	311.96KB	Share
NSB Resignation of CEO
01/12/23	PRICE SENSITIVE	178.63KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	357.42KB	Share
NSB Appointment of CEO
31/08/23	PRICE SENSITIVE	154.04KB	Share
NSB 2023 Annual Report and Appendix 4E
25/08/23	PRICE SENSITIVE	1.6MB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	339.28KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	309.87KB	Share
NSB Positive treatment effect in MS animal study
14/03/23	PRICE SENSITIVE	1.06MB	Share
NSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.2MB	Share
NSB R&D Tax Incentive Refund Received
02/02/23	PRICE SENSITIVE	116.37KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	283.22KB	Share
NSB NSB files new patent
05/12/22	PRICE SENSITIVE	434.32KB	Share
NSB Appointment of Interim CEO
23/11/22	PRICE SENSITIVE	170.98KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	283.14KB	Share
NSB Investor Update Presentation
20/09/22	PRICE SENSITIVE	1.05MB	Share
NSB CEO Resignation
09/09/22	PRICE SENSITIVE	124.53KB	Share
NSB HREC decision to not approve Phase I Clinical Trial
07/09/22	PRICE SENSITIVE	129.59KB	Share
NSB NeuroScientific releases FY2022 Results
30/08/22	PRICE SENSITIVE	223.9KB	Share
NSB 2022 Annual Report and Appendix 4E
30/08/22	PRICE SENSITIVE	1.85MB	Share
NSB R&D Tax Incentive Refund Received
17/08/22	PRICE SENSITIVE	139.55KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	292.44KB	Share
NSB HREC Submission for Phase I Clinical Trial
12/07/22	PRICE SENSITIVE	138.38KB	Share
NSB First Subject Recruited for Early-Phase Clinical Trial
30/06/22	PRICE SENSITIVE	142.11KB	Share
NSB Positive results in MS animal study
15/06/22	PRICE SENSITIVE	147.01KB	Share
NSB Ethics Approval Granted for Early-Phase Clinical Trial
07/06/22	PRICE SENSITIVE	140.53KB	Share
NSB HREC Submission for early-phase Clinical Trial
11/05/22	PRICE SENSITIVE	149.59KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	284.15KB	Share
NSB Positive safety result supports advance to clinical trials
13/04/22	PRICE SENSITIVE	144.93KB	Share
NSB New data demonstrates EmtinB activity in autoimmune diseases
11/03/22	PRICE SENSITIVE	258.11KB	Share
NSB NSB 1HY22 Key Activity Highlights
28/02/22	PRICE SENSITIVE	223.32KB	Share
NSB Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	885.91KB	Share
NSB Successful completion of key studies in lead up to Phase I
08/02/22	PRICE SENSITIVE	144.51KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	300.57KB	Share
NSB Positive off-target safety assessment of EmtinB
24/12/21	PRICE SENSITIVE	144.05KB	Share
NSB Positive results in biomarker characterisation of Emtins
21/12/21	PRICE SENSITIVE	421.77KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	279.9KB	Share
NSB Completion of Safety Pharmacology Studies
18/10/21	PRICE SENSITIVE	143.03KB	Share
NSB NSB Receives R&D Advance & Overseas Finding
03/09/21	PRICE SENSITIVE	114.12KB	Share
NSB Positive Results in Multiple Sclerosis Study
31/08/21	PRICE SENSITIVE	248.06KB	Share
NSB 2021 Annual Report and Appendix 4E
27/08/21	PRICE SENSITIVE	910.83KB	Share
NSB Results from Pulmonary Studies Clarification
20/08/21	PRICE SENSITIVE	159.86KB	Share
NSB Trading Halt
19/08/21	PRICE SENSITIVE	587.81KB	Share
NSB Pause in Trading
19/08/21	PRICE SENSITIVE	118.08KB	Share
NSB Results from Pulmonary Studies
19/08/21	PRICE SENSITIVE	161.11KB	Share
NSB Quarterly Update and Appendix 4C
30/07/21	PRICE SENSITIVE	349.07KB	Share
NSB Successful completion of pivotal ocular safety study
01/07/21	PRICE SENSITIVE	169.24KB	Share
NSB Trading Halt
30/06/21	PRICE SENSITIVE	589.64KB	Share
NSB Pause in Trading
30/06/21	PRICE SENSITIVE	117.12KB	Share
NSB NSB partners with Linear Research for Phase I Clinical Study
23/06/21	PRICE SENSITIVE	174.21KB	Share
NSB R&D Tax Rebate Received
31/05/21	PRICE SENSITIVE	106.28KB	Share
NSB Update on Pivotal Ocular Safety Studies
05/05/21	PRICE SENSITIVE	618.43KB	Share
NSB Appendix 4C - quarterly
30/04/21	PRICE SENSITIVE	280.13KB	Share
NSB Manufacturing Update
28/04/21	PRICE SENSITIVE	81.69KB	Share
NSB Key Executive Appointments to Support Clinical Studies
31/03/21	PRICE SENSITIVE	109.58KB	Share
NSB Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	458.12KB	Share
NSB Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	298.77KB	Share
NSB NSB to investigate treatment for post-COVID Fibrosis
20/11/20	PRICE SENSITIVE	219.65KB	Share
NSB Trading Halt
19/11/20	PRICE SENSITIVE	264.08KB	Share
NSB Strategic Placement to AlphaSwiss Partners
11/11/20	PRICE SENSITIVE	130.2KB	Share
NSB Trading Halt
09/11/20	PRICE SENSITIVE	601.76KB	Share
NSB Appendix 4C - quarterly
30/10/20	PRICE SENSITIVE	321.92KB	Share
NSB Appendix 4E and Annual Report
28/08/20	PRICE SENSITIVE	911.6KB	Share
NSB Updated Appendix 4C
12/08/20	PRICE SENSITIVE	315.52KB	Share
NSB Full Report from Multiple Sclerosis Study
04/08/20	PRICE SENSITIVE	349.04KB	Share
NSB Appendix 4C - quarterly
31/07/20	PRICE SENSITIVE	302.15KB	Share
NSB EmtinB Positive Results in MS
14/07/20	PRICE SENSITIVE	203.32KB	Share
NSB Final Report received for Glaucoma Study
04/05/20	PRICE SENSITIVE	267.07KB	Share
NSB Appendix 4C - quarterly
30/04/20	PRICE SENSITIVE	710.11KB	Share
NSB Positive Results in MS Study
18/03/20	PRICE SENSITIVE	454.02KB	Share
NSB Trading Halt
16/03/20	PRICE SENSITIVE	429.56KB	Share
NSB Positive Results in Glaucoma Pig Model
11/03/20	PRICE SENSITIVE	167.4KB	Share
NSB Trading Halt
09/03/20	PRICE SENSITIVE	113.9KB	Share
NSB Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	348.73KB	Share
NSB Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	177.13KB	Share
NSB Additional US Patent granted
22/01/20	PRICE SENSITIVE	153.53KB	Share
NSB CVN Model Indicates Neuroprotective Properties of EmtinB
06/12/19	PRICE SENSITIVE	399.54KB	Share
NSB NSB - Company Update
02/12/19	PRICE SENSITIVE	172.05KB	Share
NSB AGM Address
29/11/19	PRICE SENSITIVE	1.51MB	Share
NSB Appendix 4C - quarterly
28/10/19	PRICE SENSITIVE	176.85KB	Share
NSB EmtinB Can Become a Revolutionary Treatment for Glaucoma
01/10/19	PRICE SENSITIVE	398.9KB	Share
NSB Trading Halt
27/09/19	PRICE SENSITIVE	239.28KB	Share
NSB NSB Receives R&D Advanced Overseas Finding
02/09/19	PRICE SENSITIVE	153.46KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.5¢		Change -0.015(8.33%)		Mkt cap ! $54.87M

Open	High	Low	Value	Volume
17.5¢	18.0¢	16.5¢	$35.84K	210.2K

Buyers (Bids)

No.	Vol.	Price($)
3	74350	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	223089	4

View Market Depth

No.	Vol.	Price($)
3	74350	0.165
5	211876	0.160
2	42209	0.155
4	30574	0.150
1	300000	0.145

Price($)	Vol.	No.
0.180	223089	4
0.185	86585	3
0.190	200000	1
0.195	38000	3
0.200	374501	5

Last trade - 16.10pm 18/09/2025 (20 minute delay)


Last 16.5¢		Change -0.015 ( 2.94 %)
Open	High	Low	Volume
17.5¢	17.5¢	16.5¢	177708
Last updated 15.22pm 18/09/2025 ?

NSB (ASX) Chart

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories